Cargando…

Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis

Systemic sclerosis (SSc) is a connective tissue disease with an unknown etiology. Clinically, it is characterized by localized or diffuse skin thickening and fibrosis. The pathogenesis of SSc includes microvascular injury, autoimmune-mediated inflammation, and fibroblast activation. These processes...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Yang, Yanli, Gao, Xiang, Gao, Wenqin, Zhang, Liyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485262/
https://www.ncbi.nlm.nih.gov/pubmed/37693906
http://dx.doi.org/10.3389/fphar.2023.1263839
_version_ 1785102746028867584
author Zhang, Yan
Yang, Yanli
Gao, Xiang
Gao, Wenqin
Zhang, Liyun
author_facet Zhang, Yan
Yang, Yanli
Gao, Xiang
Gao, Wenqin
Zhang, Liyun
author_sort Zhang, Yan
collection PubMed
description Systemic sclerosis (SSc) is a connective tissue disease with an unknown etiology. Clinically, it is characterized by localized or diffuse skin thickening and fibrosis. The pathogenesis of SSc includes microvascular injury, autoimmune-mediated inflammation, and fibroblast activation. These processes interact and contribute to the diverse clinicopathology and presentation of SSc. Given the limited effectiveness and substantial side effects of traditional treatments, the treatment strategy for SSc has several disadvantages. Mesenchymal stem cells (MSCs) are expected to serve as effective treatment options owing to their significant immunomodulatory, antifibrotic, and pro-angiogenic effects. Exosomes, secreted by MSCs via paracrine signaling, mirror the effect of MSCs as well as offer the benefit of targeted delivery, minimal immunogenicity, robust reparability, good safety and stability, and easy storage and transport. This enables them to circumvent the limitations of the MSCs. When using exosomes, it is crucial to consider preparation methods, quality standards, and suitable drug delivery systems, among other technical issues. Therefore, this review aims to summarize the latest research progress on MSCs and exosomes in SSc, offering novel ideas for treating SSc.
format Online
Article
Text
id pubmed-10485262
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104852622023-09-09 Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis Zhang, Yan Yang, Yanli Gao, Xiang Gao, Wenqin Zhang, Liyun Front Pharmacol Pharmacology Systemic sclerosis (SSc) is a connective tissue disease with an unknown etiology. Clinically, it is characterized by localized or diffuse skin thickening and fibrosis. The pathogenesis of SSc includes microvascular injury, autoimmune-mediated inflammation, and fibroblast activation. These processes interact and contribute to the diverse clinicopathology and presentation of SSc. Given the limited effectiveness and substantial side effects of traditional treatments, the treatment strategy for SSc has several disadvantages. Mesenchymal stem cells (MSCs) are expected to serve as effective treatment options owing to their significant immunomodulatory, antifibrotic, and pro-angiogenic effects. Exosomes, secreted by MSCs via paracrine signaling, mirror the effect of MSCs as well as offer the benefit of targeted delivery, minimal immunogenicity, robust reparability, good safety and stability, and easy storage and transport. This enables them to circumvent the limitations of the MSCs. When using exosomes, it is crucial to consider preparation methods, quality standards, and suitable drug delivery systems, among other technical issues. Therefore, this review aims to summarize the latest research progress on MSCs and exosomes in SSc, offering novel ideas for treating SSc. Frontiers Media S.A. 2023-08-25 /pmc/articles/PMC10485262/ /pubmed/37693906 http://dx.doi.org/10.3389/fphar.2023.1263839 Text en Copyright © 2023 Zhang, Yang, Gao, Gao and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Yan
Yang, Yanli
Gao, Xiang
Gao, Wenqin
Zhang, Liyun
Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis
title Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis
title_full Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis
title_fullStr Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis
title_full_unstemmed Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis
title_short Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis
title_sort research progress on mesenchymal stem cells and their exosomes in systemic sclerosis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485262/
https://www.ncbi.nlm.nih.gov/pubmed/37693906
http://dx.doi.org/10.3389/fphar.2023.1263839
work_keys_str_mv AT zhangyan researchprogressonmesenchymalstemcellsandtheirexosomesinsystemicsclerosis
AT yangyanli researchprogressonmesenchymalstemcellsandtheirexosomesinsystemicsclerosis
AT gaoxiang researchprogressonmesenchymalstemcellsandtheirexosomesinsystemicsclerosis
AT gaowenqin researchprogressonmesenchymalstemcellsandtheirexosomesinsystemicsclerosis
AT zhangliyun researchprogressonmesenchymalstemcellsandtheirexosomesinsystemicsclerosis